Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 8, 2013, Pages 2963-2968

  Wen, Xiangshu ^a   Rao, Ping ^a,e   Carreño, Leandro J ^b,c   Kim, Seil ^a   Lawrenczyk, Agnieszka ^a   Porcelli, Steven A ^b   Cresswell, Peter ^d   Yuan, Weiming ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHILE   (Chile)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor immunity; Humanized mouse; Immunotherapy

Indexed keywords

CD1D ANTIGEN; CD4 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; C57BL 6 MOUSE; CELL SELECTION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, CD1D; BASE SEQUENCE; CELL LINE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 84874259306     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300200110     Document Type: Article

References (31)

1. Brigl M, Brenner MB (2004) CD1: Antigen presentation and T cell function. Annu Rev Immunol 22:817-890.
2. Pellicci DG, et al. (2009) Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 31 (1):47-59.
3. McCarthy C, et al. (2007) The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 204 (5):1131-1144.
4. Borg NA, et al. (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (7149):44-49.
5. Sugita M, et al. (2002) Failure of trafficking and antigen presentation by CD1 in AP-3-deficient cells. Immunity 16 (5):697-706.
6. Elewaut D, et al. (2003) The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. J Exp Med 198 (8):1133-1146.
7. Kita H, et al. (2002) Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123 (4):1031-1043.
8. Im JS, et al. (2008) Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin Immunol 127 (2):214-224.
9. Kawano T, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (5343):1626-1629.
10. Hayakawa Y, Rovero S, Forni G, Smyth MJ (2003) Alpha-galactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 100 (16):9464-9469.
11. Crowe NY, Smyth MJ, Godfrey DI (2002) A critical role for natural killer T cells in im-munosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196 (1):119-127.
12. Exley MA, Nakayama T (2011) NKT-cell-based immunotherapies in clinical trials. Clin Immunol 140 (2):117-118.
13. Schümann J, et al. (2005) Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Valpha14i NKT cells. J Immunol 175 (11):7303-7310.
14. Wang B, et al. (2001) Human CD1d functions as a transplantation antigen and a restriction element in mice. J Immunol 166 (6):3829-3836.
15. Geng Y, Laslo P, Barton K, Wang CR (2005) Transcriptional regulation of CD1D1 by Ets family transcription factors. J Immunol 175 (2):1022-1029.
16. Chen QY, Jackson N (2004) Human CD1D gene has TATA boxless dual promoters: An SP1-binding element determines the function of the proximal promoter. J Immunol 172 (9):5512-5521.
17. Chen YH, et al. (1999) Expression of CD1d2 on thymocytes is not sufficient for the development of NK T cells in CD1d1-deficient mice. J Immunol 162 (8):4560-4566.
18. Park SH, Roark JH, Bendelac A (1998) Tissue-specific recognition of mouse CD1 molecules. J Immunol 160 (7):3128-3134.
19. Prigozy TI, et al. (2001) Glycolipid antigen processing for presentation by CD1d molecules. Science 291 (5504):664-667.
20. Im JS, et al. (2009) Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30 (6):888-898.
21. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR (1997) Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 6 (4):459-467.
22. Matsuda JL, et al. (2000) Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 192 (5):741-754.
23. Jahng AW, et al. (2001) Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 194 (12):1789-1799.
24. Godfrey DI, Stankovic S, Baxter AG (2010) Raising the NKT cell family. Nat Immunol 11 (3):197-206.
25. Kovalovsky D, et al. (2008) The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 9 (9):1055-1064.
26. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI (2005) Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 35 (5):1399-1407.
27. Karadimitris A, et al. (2001) Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci USA 98 (6):3294-3298.
28. Gumperz JE, Miyake S, Yamamura T, Brenner MB (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 (5):625-636.
29. Baev DV, et al. (2004) Distinct homeostatic requirements of CD4+ and CD4-subsets of Valpha24-invariant natural killer T cells in humans. Blood 104 (13):4150-4156.
30. Schmieg J, Yang G, Franck RW, Tsuji M (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198 (11):1631-1641.
31. Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3 (9):867-874.